Our Success

Founded in 2006, Stealth BioTherapeutics is a biopharmaceutical company born out of the discoveries made by Dr. Peter Scheller at the IRCM. Now in the clinical phase, it is developing therapies targeting mitochondria to treat serious genetic diseases and age-related conditions. Its lead candidate, BendaviaTM, targets conditions such as primary mitochondrial myopathy, Barth syndrome, Leber hereditary optic neuropathy, and age-related macular degeneration. A second molecule, SBT-20, is currently being evaluated for the treatment of peripheral neuropathies. A first successful treatment of a rare eye disease is a concrete illustration of the hope that these therapies bring. 

Based on discoveries made by Dr. Michel Cayouette and published in 2022, Numbio Therapeutics was founded in 2024 with the support of the IRCM’s Technology Transfer Office. This young biotechnology company, specializing in ophthalmology, is developing an innovative gene therapy targeting neurodegeneration caused by glaucoma. By focusing on modulating the Numb protein to reduce toxic levels of Tau in retinal ganglion cells, Numbio is paving the way for a unique approach capable of preserving vision and slowing the progression of the disease.

Liphorus Pharmaceuticals was founded in 2013 on the basis of Dr. Nabil G. Seidah's major discoveries at the IRCM, including the identification of the PCSK9 gene in 2002 and the development of an innovative approach to the treatment of hypercholesterolemia. Unlike injectable monoclonal antibodies that target circulating PCSK9, the technology developed at the IRCM acts within the cells themselves, paving the way for more accessible oral treatments that are likely to improve therapeutic adherence. In 2014, Liphorus successfully raised $6.4 million USD in Series A financing, solidifying its position on the international biotechnology scene.

RNA Logic is a Montreal-based biotechnology company born out of a collaboration between IRCM researchers Dr. Éric Lécuyer and Dr. Martin Sauvageau. The company combines the internationally recognized expertise of its co-founders in biology and RNA regulation, artificial intelligence, and RNA therapy to support innovation in the next generation of RNA-based precision medicines.